Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Key updates in therapies for acute leukemias from ASH 2018

Daniel DeAngelo • 6 Dec 2018
ASH 2018
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Leukemia Venetoclax

Daniel DeAngelo, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, gives his take on the highlights for acute leukemia from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

More from Daniel DeAngelo

1:36
IMGN632: a novel CD123-targeted antibody-drug conjugate for R/R BPDCN
Daniel DeAngelo • 3 Dec 2020
1:36
Diagnostic pathology is crucial to guide treatment options
Daniel DeAngelo • 3 Dec 2020
2:29
ASH 2020: Treatment advances in mastocytosis
Daniel DeAngelo • 3 Dec 2020
3:57
Major ALL treatment updates at ASH 2020
Daniel DeAngelo • 3 Dec 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals